Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）

This is a randomized, open-label, multi-center, phase III clinical study, aiming to evaluate the efficacy and safety of SYS6010 versus platinum-based chemotherapy in participants with EGFR-mutated locally advanced or metastatic NSCLC who have failed EGFR TKI therapy. This study implemented a hierarchical testing strategy to control the overall Type I error at a one-sided alpha level of 0.025. If the null hypothesis for PFS was rejected, the full alpha (0.025) was recycled for OS analysis.